抄録
The patient was a 52-year-old female who was diagnosed with postmenopausal lymphangioleiomyomatosis (LAM). Although she was placed on a treatment of luteinizing hormone releasing hormone agonist (LHRH-A) for two months, she could not tolerate this therapy due to adverse reactions. For the subsequent 6.5 years, her clinical course was carefully monitored and the results of clinical observation, pulmonary function tests and a CT of the chest showed no clear signs of aggravation. Our literature review yielded two patients who were left untreated although their clinical progress was slow and mild. The possibility was suggested that some patients with postmenopausal LAM could be carefully observed.
